Nov 06, 2026 12:00pm EST Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
Nov 06, 2026 9:00am EST Immunocore reports third quarter financial results and provides a business update
Oct 29, 2026 9:00am EDT Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Oct 15, 2026 7:00am EDT Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Sep 14, 2026 7:00am EDT Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Aug 06, 2026 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Jul 30, 2026 7:00am EDT Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
May 31, 2026 8:00am EDT Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
May 06, 2026 7:00am EDT Immunocore reports first quarter financial results and provides a business update